Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Pharmacogenetics of Warfarin in a Diverse Patient Population.

Mak M, Lam C, Pineda SJ, Lou M, Xu LY, Meeks C, Lin C, Stone R, Rodgers K, Mitani G.

J Cardiovasc Pharmacol Ther. 2019 May 7:1074248419843530. doi: 10.1177/1074248419843530. [Epub ahead of print]

PMID:
31064211
2.

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.

Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R Jr.

Pharmacogenomics. 2008 Feb;9(2):169-78. doi: 10.2217/14622416.9.2.169.

PMID:
18370846
3.

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ.

Br J Clin Pharmacol. 2010 Aug;70(2):234-40. doi: 10.1111/j.1365-2125.2010.03698.x.

4.

Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.

Pathare A, Al Khabori M, Alkindi S, Al Zadjali S, Misquith R, Khan H, Lapoumeroulie C, Paldi A, Krishnamoorthy R.

J Hum Genet. 2012 Oct;57(10):665-9. doi: 10.1038/jhg.2012.94. Epub 2012 Aug 2.

PMID:
22854539
5.

Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.

Di Fusco D, Ciccacci C, Rufini S, Forte V, Novelli G, Borgiani P.

Thromb Res. 2013 Jul;132(1):123-6. doi: 10.1016/j.thromres.2013.05.002. Epub 2013 May 30.

PMID:
23726967
6.

Warfarin Therapy and VKORC1 and CYP Genotype.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2012 Mar 8 [updated 2018 Jun 11].

7.

Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.

Giri AK, Khan NM, Grover S, Kaur I, Basu A, Tandon N, Scaria V; Consortium IGV; INDICO, Kukreti R, Brahmachari SK, Bharadwaj D.

Pharmacogenomics. 2014 Jul;15(10):1337-54. doi: 10.2217/pgs.14.88.

PMID:
25155935
8.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F.

Heart Vessels. 2010 Mar;25(2):155-62. doi: 10.1007/s00380-009-1177-7. Epub 2010 Mar 26.

PMID:
20339978
9.

Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.

Gaikwad T, Ghosh K, Kulkarni B, Kulkarni V, Ross C, Shetty S.

Eur J Pharmacol. 2013 Jun 15;710(1-3):80-4. doi: 10.1016/j.ejphar.2013.04.006. Epub 2013 Apr 16.

PMID:
23602689
10.

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ.

Pharmacogenomics. 2010 Jun;11(6):781-91. doi: 10.2217/pgs.10.49.

11.

Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.

Zhang J, Chen Z, Chen C.

Meta Gene. 2016 Jul 5;9:197-209. doi: 10.1016/j.mgene.2016.07.002. eCollection 2016 Sep. Review.

12.

Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.

Chen W, Wu L, Liu X, Shen Y, Liang Y, Zhu J, Tan H, Yang Y, Liu Q, Wang M, Liu L, Wang X.

Int J Clin Pharmacol Ther. 2017 Feb;55(2):126-132. doi: 10.5414/CP202494.

PMID:
27117036
13.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H.

Pharmacogenet Genomics. 2006 Feb;16(2):101-10.

PMID:
16424822
14.

Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.

Yang J, Chen Y, Li X, Wei X, Chen X, Zhang L, Zhang Y, Xu Q, Wang H, Li Y, Lu C, Chen W, Zeng C, Yin T.

Int J Cardiol. 2013 Oct 9;168(4):4234-43. doi: 10.1016/j.ijcard.2013.07.151. Epub 2013 Aug 7. Review.

PMID:
23932037
15.

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.

Liang R, Li L, Li C, Gao Y, Liu W, Hu D, Sun Y.

J Thromb Thrombolysis. 2012 Jul;34(1):120-5. doi: 10.1007/s11239-012-0725-7.

PMID:
22528326
16.

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Stehle S, Kirchheiner J, Lazar A, Fuhr U.

Clin Pharmacokinet. 2008;47(9):565-94. Review.

PMID:
18698879
17.

Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.

Ghozlan MF, Foad DA, Darwish YW, Saad AA.

Blood Coagul Fibrinolysis. 2015 Jul;26(5):499-504. doi: 10.1097/MBC.0000000000000272.

PMID:
25699611
18.

Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.

Kudzi W, Ahorhorlu SY, Dzudzor B, Olayemi E, Nartey ET, Asmah RH.

BMC Res Notes. 2016 Dec 9;9(1):507.

19.

Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients.

Cho HJ, Sohn KH, Park HM, Lee KH, Choi B, Kim S, Kim JS, On YK, Chun MR, Kim HJ, Kim JW, Lee SY.

Pharmacogenomics. 2007 Apr;8(4):329-37.

PMID:
17391071
20.

Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies.

Tang W, Shi QP, Ding F, Yu ML, Hua J, Wang YX.

Int J Clin Pharmacol Ther. 2017 Apr;55(4):304-321. doi: 10.5414/CP202833. Review.

PMID:
28025970

Supplemental Content

Support Center